Portfolio Dashboard
Real-time overview of literature surveillance across all products under safety monitoring.
Last sync: 2 min ago
Filters:
Showing 4 of 4 products
Product Surveillance Status
● LiveUpdated 2 min ago
| Product | Active Substance | Frequency | Last Search | Next Search | Retrieved | Potential ICSRs | Review Status | Owner | Countries |
|---|---|---|---|---|---|---|---|---|---|
Cardiomab | cardiomabumab (anti-PCSK9 mAb) | Weekly | 2026-07-21 | 2026-07-28 | 412 | 8 | On Track | Dr. Elena Vasquez | USEUJP |
Hepatora | hepatorinib (small-molecule TKI) | Bi-weekly | 2026-07-14 | 2026-07-28 | 289 | 5 | Due Soon | Dr. Marcus Lindqvist | USEUCAAU |
Neurovex | neurovexine ER (extended-release tablet) | Weekly | 2026-07-19 | 2026-07-26 | 521 | 11 | Overdue | Dr. Priya Anand | USEUJPBRIN |
Glycostat | glycostatine + metformin HCl (combination) | Monthly | 2026-07-02 | 2026-08-02 | 178 | 3 | Awaiting Review | Dr. Sven Eriksson | USEU |
Weekly Screening Volume
articles / week198
W-5
221
W-4
245
W-3
231
W-2
268
W-1
247
Current
6-week trend: +13.4% vs prior period
AI vs Human Agreement
AI92.4%agreement
● Agreed (auto-accept)92.4%
● Disagreed (human override)5.1%
● Deferred to human2.5%
Review Turnaround
Avg. Abstract Review2.3 min
target ≤ 5 min
Full-Text Turnaround1.8 days
target ≤ 3 days
ICSR Case Processing3.2 days
target ≤ 4 days (regulatory clock)
Search Completion by Product
last 12 monthsCardiomab50/52 96%
Hepatora24/26 92%
Neurovex47/52 90%
Glycostat11/12 92%
Portfolio avg: 94.2% completion
Regulatory Clock Alerts
2 criticalNeurovex36h left
Case PV-2026-0419 · Due 2026-07-29 17:00
Hepatora18h left
Case PV-2026-0388 · Due 2026-07-28 09:00
Cardiomab96h left
Case PV-2026-0502 · Due 2026-08-01 17:00
Source Connectivity
4 sourcesPubMed (E-utilities)
last sync 2 min ago
Operational
240 ms
Embase (Ovid adapter)
last sync 14 min ago
Degraded — retry queued
4200 ms
Local Repository
last sync 1 min ago
Operational
12 ms
Manual Submissions
last sync 3 hr ago
Operational
⚠️AI-assisted triage and ICSR flagging are decision-support aids. All potential adverse-event cases require qualified human review before regulatory submission. This prototype is not a validated safety database.